Mechanisms of morphine–venlafaxine interactions in diabetic neuropathic pain model
- 1 February 2015
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 67 (1) , 90-96
Abstract
We investigated the possible mechanisms involved in the interactions of venlafaxine (VFX), a selective serotonin and noradrenaline reuptake inhibitor, and morphine (MRF), an opioid receptor agonist, after acute and chronic VFX treatment in diabetic neuropathic pain model (DNPM). The studies were performed on male rats. The changes in nociceptive thresholds were determined by using mechanical stimuli (the Randall-Selitto and the von Frey tests). Diabetes was induced by intramuscular administration of streptozotocin. In order to investigate the mechanism of interaction, animals were also pretreated with naloxone (NLX), a nonselective opioid antagonist, yohimbine (YOH), a nonselective α2-adrenergic antagonist, and p-chloroamphetamine (PCA), a neurotoxin that destroys serotonergic neurons. The μ-opioid receptors' density was determined with the use of radioligand binding assay. VFX potentiated antinociceptive action of MRF after acute administration of VFX and this effect was decreased by pretreatment of NLX, YOH and PCA. On the contrary, VFX administered for 21 days prior to MRF significantly decreased the analgesic action of MRF; this effect was augmented only after YOH pretreatment. Also, 21-days administration of VFX caused decreasing tendency in the number of μ-opioid receptors in the brain stem. The results of our study show that single administration of VFX potentiates antinociceptive action of morphine in DNPM. This effect is probably mediated by both, noradrenergic and serotonergic systems. On the other hand, 21-days administration of VFX significantly decreases analgesic action of MRF. Moreover, there is a possibility that VFX acts as an antagonist of N-methyl-d-aspartate receptors.Keywords
This publication has 40 references indexed in Scilit:
- Drugs for neuropathic painBMJ, 2013
- Modification of morphine analgesia by venlafaxine in diabetic neuropathic pain modelPharmacological Reports, 2012
- Efficacy of Antidepressants as Analgesics: A ReviewThe Journal of Clinical Pharmacology, 2012
- Evidence‐based Guideline: Treatment of Painful Diabetic NeuropathyPM&R, 2011
- Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapiesCurrent Medical Research and Opinion, 2010
- A review of SSRIs and SNRIs in neuropathic painExpert Opinion on Pharmacotherapy, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- The Synergistic Interaction Between Morphine and Maprotiline After Intrathecal Injection in RatsAnesthesia & Analgesia, 2009
- Painful diabetic neuropathy: treatment and future aspectsDiabetes/Metabolism Research and Reviews, 2008
- Modification of antiallodynic and antinociceptive effects of morphine by peripheral and central action of fluoxetine in a neuropathic mice modelActa Biologica Hungarica, 2007